Cargando…
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
Metastatic colorectal cancer (CRC) is incurable for most patients. Since mammalian target of rapamycin (mTOR) has been suggested as a crucial modulator of tumor biology, we aimed at evaluating the effectiveness of mTOR targeting for CRC therapy. To this purpose, we analyzed mTOR expression and the e...
Autores principales: | Francipane, Maria Giovanna, Lagasse, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875761/ https://www.ncbi.nlm.nih.gov/pubmed/24185040 |
Ejemplares similares
-
mTOR pathway in colorectal cancer: an update
por: Francipane, Maria Giovanna, et al.
Publicado: (2013) -
Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
por: Amin, Anubhav G., et al.
Publicado: (2021) -
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
por: Waetzig, Rebecca, et al.
Publicado: (2021) -
Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors †
por: Shaik, Althaf, et al.
Publicado: (2018) -
Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure
por: Francipane, Maria Giovanna, et al.
Publicado: (2019)